## Please type a plus sign (+) inside this box --> +

UTILITY			Attorney Docket No.		PC19084/AG0116-US					
PATENT APPLICATION			First Inventor		David Matthews					
٦	<b>TRANSM</b>	IITTAL	Title		PIN1 PEPTIDYL-PROLYL ISOMERASE POLYPEPTIDES, THEIR CRYSTAL STRUCTURES, AND USE THEREOF FOR DRUG DESIGN					
(Only for new no	onapplications under	: 37C.F.R. 61.53(b))	Express Mail L	abel No.	EV 341079666 US					
	APPLIC	n contents.	ADI	DRESS TO:		p <u>Patent Applications</u> sioner for Patents				
	·					Alexand	Irla, VA 22313-1450			
(Si	ubmit an original, a	al Form (e.g., <i>PTO/SB/</i> and a duplicate for fee process		CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)      Nucleotide and/or Amino Acid Sequence Submission						
	Applicant claim See 37 CFR 1.	s small entity status 27		(if applicable, all necessary)						
	•	Total Pages] gement set forth below)	71	a. Computer Readable Copy (CRF)						
		title of the Invention			b. Specification	•	<u> </u>			
		ences to Related Applic Regarding Fed sponsore			i. U CD-F	ROM or CD-	R (2 copies)			
	- Reference to			ii. Pape	r					
		er program listing apper			c Stater	ment verifyir	ng identity of above copies			
	•	of the Invention			ACCOMPAN	YING APP	LICATION PARTS			
	<ul> <li>Brief Summary of the Invention</li> <li>Brief Description of the Drawings (if filed)</li> </ul>				Assignment P	apers (cove	er sheet & document(s))			
	- Detailed Des - Claim(s)			10.	37 CFR 3.73(b) Statement (when there is an assignee)					
	* Abstract of t	ne Disclosure		11.	English Trans	lation Docu	ment (if applicable)			
4.	Drawing(s) (35 (	<i>U.S.C. 113</i> ) [Total sheet	s D	12.	Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations					
5. 🔲 c	Dath or Declara	tion [Total page	s [4]	13.	Preliminary Amendment					
	<del></del>	executed (original or cop		14.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
		m a prior application (37 CF inuation/divisional with Box	- ' ' ' '	15.	Certified Copy of Priority Document(s)					
	named	DELETION OF INVE d statement attached deleting in the prior application, see	g inventor(s)	16.	(if foreign priority is claimed)  Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35					
1.63(d)(2) and 1.33(b).  6 Application Data Sheet. See 37 CFR 1.76					or its equivale	ent.				
				17.	Other:					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.										
	Continuation	Divisional	Continuation	-in-part (CII	-part (CIP) of prior application No:/					
Prior application information: Examiner Group/Art Unit:										
For CONTINUATION OR DIVISIONAL APPS only. The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts										
18. CORRESPONDENCE ADDRESS										
Customer Number or Bar Code Label  (Insert Customer No. or Attach bar code label here) or Correspondence address below  28940										
Name	Agouron Pharmaceuticals, Inc.									
Address	10777 Science Center Drive									
City	San Diego	State	CA		Zip Code	92121				
Country	USA	Т	elephone	858/62	2-8060 Fax		858/678-8233			
NAME	E (Print/type)	1	Registratio	<b>n No</b> . (Attorney/	(Agent)	39,313				
Ciana	· · · · · · · · · · · · · · · · · · ·	1/ 1 1/1-	1 //		0-4-		Luk & 2002	1		



Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEFARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB number.

FEE TRANSMITTAL					Complete if Known								
					Application Number							_]	
					Filing Date				<u> </u>				
for FY 2003						med Inve	entor		David Matth ws			٦	
						er Name						Ü	
Applicant claims small status. See 37 CFR 1.27					Art Unit							⋾	
Total Amount of Payment (\$)2,910.00						y Docket	No.		PC19084/AG0116-US			7	
	METHOD (	OF PAY	MENT (check all that apply)	·								1	
☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None						3. ADDITIONAL FEES							
Deposit A	ccount:				Large	Entity	Small	Entity					
Deposit Account 500329				Fee Code	Fee	Fee Code	Fee (\$)	Fee Descrip	ption	Fee Paid			
Number 500329					0000	(\$)	Oode	(Ψ)			Paid		
Deposit						130	2051	65	Surcharge - late fee or	oath		ı l	
Account Name Agouron Pharmaceuticals, Inc.												il	
The Commissioner is authorized to: (check all that apply)						50	2052	<b>25</b>	Surcharge-late filing fe sheet	e or cover			
	e(s) indicat	ed belo	w 🛛 Credit any overpa	yments	1053	130	1053	130	Non-English specificati	on		il	
☐ Charge any additional fee(s) during the pendency of this application						2,520	1812	2,520	For filing a request for	reexamination			
Charge fee(s) indicated below, except for the filling fee to the above-identified deposit account.					1804	920*	1804	920*	Requesting publication Examiner action	of SIR prior to			
		•			1805	1,840*	1805	1,840*	Requesting publication Examiner action	of SIR after			
FEE CALCULATION					1251	110	2251	55	Extension for reply with				
BASIC FILING FEE     Large Entity					1252	410	2252	205	Extension for reply with month				
Large Entity	Fee	Fee	Fee Description Fe	e Paid	1253	930	2253	465	Extension for reply with				
Fee Fee Code (\$)	Code	(\$)			1254	1,450	2254	725	Extension for reply with month				
1001 750	2001	375	, ,	750	1255	1,970 320	2255 2401	985 160	Extension for reply with Notice of Appeal	nin fifth month	-		
1002 330 1003 520	2002	165 260	Design filing fee Plant filing fee		1401 1402	320	2401	160	Filing a brief in support	of an appeal		1	
1004 750	2004	375	Reissue filina fee		1403	280	2403	140	Request for oral hearing				
1005 160	2005	80	filing fee	750	1451 1452	1,510	1451 2452	1,510 55	Petition to institute a purposeeding Petition to revive - una				
SUBTOTAL (1) 750						110							
2. EXTRA CLA	IM FEES I	FOR UT	TILITY AND REISSUE		1453	1,300	2453	650	Petition to revive - unin				
			Extra Fee from F	ee Paid	1501	1,300	2501	650	Utility issue fee (or reis	sue)	الـــا		
Total Claims	56 -	20**=	36 x 18 =	648	1502	470	2502	235	Design issue fee				
Independent	21 .	3**=	18 x 84 =	1512	1503	630	2503	315	Plant issue fee				
Claims						400	4400	100	Detitions to the Commi	ionionos			
Multiple Dependent = 0					1460 1807	130 50	1460 1807	130 50	Petitions to the Commi Processing fee under 3		-		
** or number previously paid, if greater; For Reissues, see below  Large Entity Small Entity					1801	750	2801	375	Request for Continued E	,			
Fee Fee	Fee	Fee	Fee Description		1806	180	1806	180	(RCE) Submission of Information				
Code (\$) 1202 18	2202	<b>(\$)</b> 9	Claims in excess of 20		8021	40	8021	40	Statement Recording each patent per property (times nur				
1201 84	2201	42	Independent claims in excess	of 3	1809	750	2809	375	properties) Filing a submission after				
1203 280	2203	140	Multiple dependent claim, if no		1810	750	2810	375	(37 CFR 1.129(a)) For each additional inv	•			
1203 260	2204	42	**Reissue independent claims over					2.0	be examined (37 CFR				
original patent			Other Fee (specify)  *Reduced by Basic Filing Fee Paid							Ц			
1205 18 2205 <sup>9</sup> **Reissue claims in excess of 20 and over original patent					Heduce	u by Basic	riling Fee	rai0					
SUBTOTAL (2) (\$) 2160									SUBTOTAL	(3) (\$)			
SUBMITTED		Complete (if Applicable)						$\neg$					
Name (Printed/Type) Karl Neidert							<b>6</b> 2003		Reg. Number 39,313				
Cianatura		. 71/	A 1/1 A F		Date	I links	✓ 2002		Telephone	<b>・ メミな/ミック-なりらり</b>			

PC19084-AG0116-US
Patent Application Transmittal

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV 341079666US in an envelope addressed to: Mail Stop Patent Applications, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 8th day of July 2003.

s/ Wall Maccles
Karl Neidert

Group Art Unit: Not yet assigned

**Examiner: Not yet assigned** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: David Matthews et al.

Serial No.: Not yet assigned

Filed: Herewith

For: PIN1 PEPTIDYL-PROLYL ISOMERASE

POLYPEPTIDES, THEIR CRYSTAL STRUCTURES, AND USE THEREOF FOR

**DRUG DESIGN** 

Mail Stop: Patent Applications Commissioner For Patents P.O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Utility Patent Application Transmittal 71 pages
- 2. Fee Transmittal (in duplicate)
- 3. Application Data Sheet (4 pages)
- 4. Specification (Total 71 pages)
  - Claims
  - Abstract
- 5. Return Postcard

Total Fee Due \$2,910.00 - Deposit Account

Respectfully submitted,

Date: July 8, 2003

Karl Neidert
Attorney For Applicants
Registration No. 39,313

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-8060

Fax: (858) 678-8233